#Italy #Milan #Medical Imaging #Bracco Group #ACIST Pro™

Introduction

Bracco Group and its subsidiary, ACIST Medical Systems, are proud to announce the rollout of the ACIST Pro™ Diagnostic System in selected European markets. This sophisticated technology is set to enhance precision, safety, and efficiency in image-guided cardiovascular procedures—an essential development in the evolving healthcare landscape.

A New Era in Contrast Management

ACIST Pro™ signifies a significant advancement in contrast management. This innovative system builds upon the foundation laid by the renowned ACIST CVi® system, which has already revolutionized the way contrast is managed in cardiac catheterization laboratories. The ACIST Pro™ enhances automated contrast delivery, thus promoting real-time precision and minimizing manual intervention during procedures.

The recent approval of the system bears the CE Mark, affirming its compliance with strict European Medical Device Regulations (MDR). This marks a milestone for Bracco as they continue to prioritize safety and environmental standards in their product offerings.

Key Benefits and Clinical Impact

The ACIST CVi® system has already demonstrated significant advantages over manual contrast injection, including:

• - An impressive 45 ml reduction in average contrast usage.
• - A 30% decrease in contrast-induced acute kidney injury (CI-AKI).
• - Savings of approximately 5 minutes per procedure.

These metrics illustrate not only the efficiency but also the safety improvements facilitated by the ACIST Pro™ system. By streamlining procedures, it mitigates risks associated with contrast administration while enhancing workflow in catheterization labs.

Leadership Vision

Dr. Fulvio Renoldi Bracco, CEO of Bracco Imaging, expressed his enthusiasm regarding this launch, stating, "Launching ACIST Pro™ is a critical move in our commitment to advancing precision imaging solutions across various medical specialties." He emphasized the importance of responding to the needs of modern interventional teams and how this evolution aligns with the company's long-term vision of fostering innovation in diagnostic imaging.

Brad Fox, CEO of ACIST Medical Systems, also articulated the company's commitment, explaining, "By enhancing an already trusted platform, we are proud to introduce a superior solution that significantly boosts precision and efficiency. The launch in Europe underscores our ongoing commitment to providing cutting-edge technology for clinicians engaged in cardiovascular care."

Future Prospects

Initially debuted in Japan in 2025, the ACIST Pro™ is set for widespread availability globally in 2026. Additionally, the FDA 510(k) clearance process is underway in the United States, promising a further expansion of its reach. This progressive step reflects Bracco’s and ACIST Medical Systems’ aims to exceed professional expectations while ensuring superior patient care.

Company Background

Founded in 1927, the Bracco Group has become a recognized leader in the healthcare sector, providing services across 100 countries. The commitment to innovation is illustrated by its significant investment in research and development, which amounts to approximately 9% of its annual revenue. With over 2,000 active patents globally, the organization is at the forefront of advancing diagnostic imaging technologies.

ACIST Medical Systems is renowned for its interventional and diagnostic products, specializing in advanced technologies designed for improved cardiovascular procedures. As part of the larger Bracco Group, ACIST benefits from extensive resources, contributing to ongoing advancements in cath lab technology and the assurance of greater patient care.

Conclusion

The launch of the ACIST Pro™ Diagnostic System marks a pivotal moment in cardiovascular imaging, promising to enhance safety, precision, and performance in healthcare settings. As its availability continues to expand globally, stakeholders can look forward to important contributions that both Bracco and ACIST bring to patient care and technological innovation.